 Home > Active Ingredient News > Study of Nervous System > JAMA Neurol: Safety Study of Follow-up Antiplatelet Therapy in Patients with Cerebral Hemorrhage and Stroke

JAMA Neurol: Safety Study of Follow-up Antiplatelet Therapy in Patients with Cerebral Hemorrhage and Stroke

 Last Update: 2021-09-12
 Source: Internet
 Author: User

Tags

radiopharmaceutical therapy

venom therapy

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

In the high-developed countries, at least one-third of spontaneous (non-traumatic) intracerebral hemorrhage (ICH) in adult survivors of stroke patients receiving oral anti- thrombotic (anticoagulant) drug treatment and prevention of subsequent heart blood vessel disease, even so spontaneous ICH The risk of myocardial infarction and ischemic stroke for survivors is still higher than that of the general population, and the risk of all major hemorrhagic or ischemic cardiovascular events is also higher

Thrombosis prevention heart blood vessel myocardial infarction, stroke, cardiovascular events recently researchers have published more long-term antithrombotic treatment for ICH surviving patient safety the safety of longer-term antithrombotic therapy on survival in patients with ICH researchers recently published

The study was carried out in 122 medical centers in the UK and included 537 patients.

537 patients participated in the study, with an average age of 76.

In the antiplatelet treatment group, 22 people had ICH recurrence (8.

Differences in risk of ICH recurrence between groups

Differences in ICH recurrence risk between groups Differences in ICH recurrence risk between groups

Studies believe that it is safe for patients who survive spontaneous cerebral hemorrhage and stroke to receive antiplatelet drugs for secondary prevention of the risk of major cardiovascular events and will not increase the risk of cerebral hemorrhage recurrence

Spontaneous cerebral hemorrhage and stroke survivors receive antiplatelet drugs for the secondary prevention of major cardiovascular event risks.

Original source:

Rustam Al-Shahi Salman et al.

Effects of Antiplatelet Therapy After Stroke Caused by Intracerebral Hemorrhage Extended Follow-up of the RESTART Randomized Clinical Trial.
JAMA

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.